Living with Type 1 Diabetes means managing blood sugar every single day. Many people are looking toward stem cell therapy as a way to improve their condition, but the latest evidence suggests the results are currently modest. A review of data from 169 patients found that while stem cell therapy was linked to a small drop in HbA1c levels at six months, this change was not statistically significant by the one-year mark.
The study also looked at C-peptide, which is a marker for how much insulin the body produces naturally. While there were slight improvements in these levels at both six and twelve months, the researchers noted that these gains are of limited clinical significance. No serious safety issues were reported among the participants during the study period.
It is important to keep expectations realistic right now. Because the study involved small groups and had a lot of variation between different trials, the overall certainty of the evidence is very low. More large, well-designed trials are needed before doctors can determine if this treatment offers a meaningful change for patients.
